retatrutide weight loss trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Helped Adults With Obesity
Description
which means it will need to be approved by the plan before the drug is covered
Talbot K, Wang HY
they're helping normalize it
Adaptive responses
Generally, this medication is considered safe
Their claims are largely unsupported by evidence, and their unregulated nature introduces significant safety concerns
